Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Clinical Infectious DiseasesPublished 17 April 2007Open access
Oliver A. Cornely, Johan Maertens, Mark Bresnik, Ramin Ebrahimi, Andrew J. Ullmann, Emilio Bouza
Citations731
SJR quartileQ1
SJR score2.99
SNIP2.01
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%.
Abstract
In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%. The regimen of 10 mg/kg per day demonstrated no additional benefit and higher rates of nephrotoxicity.
Keywords
Medicine
New England Journal of MedicineVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
3,297 Citations2002Raoul Herbrecht, David W. Denning +20 more
In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.
Clinical Infectious DiseasesDefining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
2,338 Citations2002S. Ascioglu, John Rex +18 more
A set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed and three levels of probability are proposed: "proven," "probable," and "possible."
Clinical Infectious DiseasesEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
1,447 Citations2002Kieren A. Marr, Rachel A. Carter +3 more
The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B--resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.
New England Journal of MedicineLiposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
1,195 Citations1999Thomas J. Walsh, Robert W. Finberg +11 more
Liposomal amphotericin B is as effective as conventional amphoteric in B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal infections, less infusion-related toxicity, and less nephrotoxicity.
New England Journal of MedicineVoriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
983 Citations2002Thomas J. Walsh, Peter G. Pappas +21 more
Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever in a randomized, international, multicenter trial.
New England Journal of MedicineCaspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia
913 Citations2004Thomas J. Walsh, Hedy Teppler +9 more
Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
Clinical Infectious DiseasesVoriconazole: A New Triazole Antifungal Agent
764 Citations2003Leonard B. Johnson, Carol A. Kauffman
Clinical Infectious DiseasesEfficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy
656 Citations2004J. Maertens, Issam Raad +12 more
Caspofungin demonstrated usefulness in the salvage treatment of IA and was observed in 37 (45%) of 83 patients, including 32 (50%) of 64 with pulmonary aspergillosis and 3 (23%) of 13 with disseminated asperGillosis.
Journal of Clinical OncologyIncreasing Volume and Changing Characteristics of Invasive Pulmonary Aspergillosis on Sequential Thoracic Computed Tomography Scans in Patients With Neutropenia
584 Citations2001Denis Caillot, Jean-François Couaillier +9 more
In patients with neutropenia, CT halo sign is a highly effective modality for IPA diagnosis, and the increase of the aspergillosis size on CT in the first days after IPA diagnosis is not correlated with a pejorative immediate outcome when using a combined medical-surgical approach.
Clinical Microbiology Reviews<i>Aspergillus</i>Infections in Transplant Recipients
569 Citations2005Nina Singh, David L. Paterson
Management of invasive aspergillosis continues to be challenging, and the mortality rate, despite the use of newer antifungal agents, remains unacceptably high.
Journal of Antimicrobial ChemotherapyChanging patterns and trends in systemic fungal infections
523 Citations2005Malcolm Richardson
Fungal opportunistic infections in persons with AIDS are no longer a major problem in developed countries, but are resulting in significant morbidity and mortality in developing countries with AIDS epidemics, and the emergence of antifungal resistance is given.
Clinical Infectious DiseasesA Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia
520 Citations2000John R. Wingard, Mary H. White +5 more
In this double-blind study to compare safety of 2 lipid formulations of amphotericin B, neutropenic patients with unresolved fever after 3 days of antibacterial therapy were randomized to receive ABLC or L Amph, and infusional reactions were less frequent with ABLC, but chills/rigors were still higher.
Antimicrobial Agents and ChemotherapySafety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with<i>Aspergillus</i>Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
401 Citations2001Thomas J. Walsh, Jesse L. Goodman +6 more
The findings indicate that L-AMB at dosages as high as 15 mg/kg/day follows nonlinear saturation-like kinetics, is well tolerated, and can provide effective therapy for aspergillosis and other filamentous fungal infections.
Journal of Antimicrobial ChemotherapyAmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
335 Citations2002Jill Adler‐Moore, Richard T. Proffitt
In animal models, AmBisome is effective in treating both intracellular (leishmaniasis and histoplasmosis) and extracellular (candidosis and aspergillosis) systemic infections and can be safely delivered at markedly high doses of amphotericin B for the treatment of systemic fungal infections.
British Journal of HaematologyLiposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections
321 Citations1998Alexander C. A. P. Leenders, Simon Daenen +10 more
A randomized multicentre study comparing liposomal amphotericin B (AmBisome, 5 mg/kg/d) to amphoteric in B deoxycholate (Am b) in the treatment of neutropenia‐associated invasive fungal infections, finding a favourable trend at day 14 and lower mortality rates in patients with documented infections.
Journal of Antimicrobial ChemotherapyEfficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
281 Citations1991Olle Ringdén, F. Meunier +10 more
It is concluded that AmBisome is an effective antifungal agent in a majority of patients with invasive or superficial fungal infections.
Clinical Infectious DiseasesAn EORTC International Multicenter Randomized Trial (EORTC Number 19923) Comparing Two Dosages of Liposomal Amphotericin B for Treatment of Invasive Aspergillosis
254 Citations1998Michael Ellis, David J. Spence +13 more
This is the first completed prospective randomized clinical efficacy trial of antifungals in the treatment of invasive aspergillosis (IA) and the first to compare the clinical efficacy of two dosages of liposomal amphotericin B (L-AmB) for IA in neutropenic patients with cancer or those undergoing bone marrow transplantation.
British Journal of HaematologyLiposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single‐centre experience of 133 episodes in 116 patients
172 Citations1994Wendy Mills, Rajesh Chopra +2 more
AmBisome is well tolerated and effective against invasive mycoses in neutropenic patients, and may salvage patients when conventional amphotericin proves excessively toxic or ineffective, as well as evaluable in those with proven aspergillosis.
Archives of Internal MedicineLiposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections
132 Citations1995Tony Ng
AmBisome is efficacious in the treatment of invasive fungal infections and provides an alternative therapy for those who fail to respond or become intolerant to conventional amphotericin B therapy.
Journal of Antimicrobial ChemotherapySusceptibility patterns of bacteria causing community-acquired respiratory infections in Spain: the SAUCE project
30 Citations2002the Spanish Surveillance Group for Respiratory Pathogens, Juan García-de-Lomas +3 more
Spanish experience with the surveillance network SAUCE is described, and the main results on antimicrobial resistance in the three key bacterial pathogens involved in community-acquired respiratory tract infections in Spain are summarized.
MycosesLiposomal amphotericin B (AmBisome<sup>®</sup>) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis
28 Citations2007Catherine Cordonnier, Mark Bresnik +1 more
The response rates observed in this analysis were consistent with previous reports for antifungal therapy with amphotericin B deoxycholate or voriconazole in the treatment of invasive aspergillosis.
Clinical Infectious DiseasesShould the Consensus Guidelines' Specific Criteria for the Diagnosis of Invasive Fungal Infection Be Changed?
27 Citations2005B.E. de Pauw, Thomas F. Patterson
It has become evident that changing medical practices with deleterious consequences for the innate immune system extend the population at risk for invasive fungal infections and has urged researchers to reconsider the continuing appropriateness of the current definitions.
Clinical Drug InvestigationEarly Pharmacokinetic and Clinical Results from a Noncomparative Multicentre Trial of Amphotericin B Encapsulated in a Small Unilamellar Liposome (AmBisome®)
25 Citations1992J Tollemar, Olle Ringdén
AmBisome® 0.5 to 4 mg/kg/day, a small unilamellar liposome encapsulating amphotericin B, was administered to 59 patients with ideologically confirmed infections and 80% of 20 evaluable patients were cured or improved when AmBISome® was used because of the prior failure of conventional amphoteric in B in a compassionate basis trial.
Journal of Antimicrobial ChemotherapyA double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections
9 Citations1991J. Kosmidis
It is suggested that once daily temafloxacin gives high rates of clinical and bacteriological success, similar to twice daily ciprofloxacins, in the management of bacterial infections in the lower respiratory tract.